Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A non-interventional, prospective cohort study of patients with relapsing Multiple Sclerosis (MS) who had initiated cladribine tablets in routine clinical practice

X
Trial Profile

A non-interventional, prospective cohort study of patients with relapsing Multiple Sclerosis (MS) who had initiated cladribine tablets in routine clinical practice

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cladribine (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms Maven4
  • Most Recent Events

    • 14 Dec 2024 New trial record
    • 20 Sep 2024 Results of subgroup analysis based on previous use of disease-modifying therapies (DMTs) by the patients of relapsing Multiple sclerosis, who had initiated cladribine tablets in real world practice, presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top